Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANJANETTE SIA LIN TAN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1154326627
CMS profile
278531
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$32,915.00

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANJANETTE SIA LIN TAN

NPI 1154326627 · CMS profile ID 278531

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154326627?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANJANETTE SIA LIN TAN, NPI 1154326627, CMS profile ID 278531. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154326627?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANJANETTE SIA LIN TAN, NPI 1154326627, CMS profile ID 278531. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154326627?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANJANETTE SIA LIN TAN, NPI 1154326627, CMS profile ID 278531, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 132 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1154326627?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $32,915.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
DEXCOM, INC. $16.7708/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301111 CMS
Amgen Inc. $17.3208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825147051 CMS
Xeris Pharmaceuticals, Inc. $16.5208/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837447681 CMS
AstraZeneca Pharmaceuticals LP $20.1007/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829345637 CMS
SANOFI-AVENTIS U.S. LLC $19.0907/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843585371 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.0307/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598340 CMS
Zealand Pharma US, Inc. $17.0007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800230697 CMS
Amarin Pharma Inc. $13.0907/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815410349 CMS
AstraZeneca Pharmaceuticals LP $17.3507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829416627 CMS
Medtronic, Inc. $14.3707/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827245987 CMS
AstraZeneca Pharmaceuticals LP $18.9707/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829411987 CMS
DEXCOM, INC. $100.8206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845301109 CMS
SANOFI-AVENTIS U.S. LLC $13.5106/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843585359 CMS
Novo Nordisk Inc $66.5406/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810808565 CMS
Novo Nordisk Inc $120.9006/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810808569 CMS
Novo Nordisk Inc $3,485.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810847629 CMS
Novo Nordisk Inc $41.9406/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810993961 CMS
Novo Nordisk Inc $121.1806/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811628227 CMS
Novo Nordisk Inc $36.4006/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811714259 CMS
Clarus Therapeutics Inc. $14.2306/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855024683 CMS
Novo Nordisk Inc $75.0306/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810670771 CMS
Novo Nordisk Inc $121.1706/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810808783 CMS
Novo Nordisk Inc $3,485.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811242713 CMS
Novo Nordisk Inc $120.8906/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811628405 CMS
Corcept Therapeutics $11.0306/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837529431 CMS
Amgen Inc. $18.1306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825147047 CMS
Novo Nordisk Inc $110.1206/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810808777 CMS
Novo Nordisk Inc $2,210.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811048171 CMS
SANOFI-AVENTIS U.S. LLC $16.1306/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843585329 CMS
AstraZeneca Pharmaceuticals LP $20.9506/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829893121 CMS
Xeris Pharmaceuticals, Inc. $16.0206/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837447675 CMS
Alexion Pharmaceuticals, Inc. $19.7506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783108881 CMS
Ascensia Diabetes Care US Inc. $11.0906/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842570805 CMS
Novo Nordisk Inc $102.8206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811337223 CMS
Novo Nordisk Inc $2,210.0006/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811721471 CMS
Horizon Therapeutics plc $18.8305/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797216699 CMS
Novo Nordisk Inc $23.0805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810993953 CMS
Novo Nordisk Inc $2,635.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811630725 CMS
AbbVie Inc. $16.5105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796133787 CMS
SANOFI-AVENTIS U.S. LLC $14.4005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843585325 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.0305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598342 CMS
Antares Pharma, Inc. $15.8805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827515387 CMS
Amarin Pharma Inc. $17.3305/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815206013 CMS
Novo Nordisk Inc $76.1005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810670767 CMS
Novo Nordisk Inc $921.9505/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811628400 CMS
Novo Nordisk Inc $3,485.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811630723 CMS
Novo Nordisk Inc $6.4705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811714257 CMS
Alexion Pharmaceuticals, Inc. $19.1505/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783108879 CMS
Amgen Inc. $16.3105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825147043 CMS
Lilly USA, LLC $24.5505/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818945124 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $52,568.95 241
PY2020 $23,788.26 161
PY2021 $32,915.00 132
PY2022 $36,369.27 154
PY2023 $33,115.69 198
PY2024 $23,930.65 125
PY2025 $56,799.36 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $505,791.02 62
PY2024 Principal investigator $464,791.31 34
PY2023 Recipient $2,277.16 4
PY2023 Principal investigator $241,514.86 19
PY2022 Recipient $5,208.02 5
PY2022 Principal investigator $335,724.89 174
PY2021 Recipient $1,124.66 7
PY2021 Principal investigator $487,292.26 233
PY2020 Recipient $7,971.99 2
PY2020 Principal investigator $80,521.82 24
PY2019 Principal investigator $135,831.64 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER OF FORT WORTH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533441
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732716
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,700.00 12/09/2025 Non-covered Recipient Entity
Fort Worth Endocrine Research Center, LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815185
Principal investigator 1 ABBVIE INC. $9,425.00 12/05/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529216
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732708
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/21/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997298
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732714
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 11/11/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997296
Principal investigator 1 ABBVIE INC. $30,555.20 11/05/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521583
Principal investigator 1 ABBVIE INC. $157.20 11/05/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521585
Principal investigator 1 ABBVIE INC. $631.74 11/05/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521587
Principal investigator 1 ABBVIE INC. $47.47 11/05/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521589
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732706
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732710
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732712
Principal investigator 1 ABBVIE INC. $12,389.00 10/09/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514655
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/09/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220997294
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,590.00 10/09/2025 Non-covered Recipient Entity
DIABETES & THYROID CENTER OF FORT WORTH PLLC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223286617
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $370.03 09/16/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220808759
Principal investigator 1 ABBVIE INC. $17,769.70 09/04/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509452
Principal investigator 1 ABBVIE INC. $3,338.20 09/02/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202506955
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 09/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732696
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 09/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732698
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732700
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 09/01/2025 Non-covered Recipient Entity
Diabetes And Thyroid Center Of Fort Worth
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220732702
Principal investigator 1 ABBVIE INC. $1,844.22 08/26/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505801
Principal investigator 1 ABBVIE INC. $18,418.40 08/06/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503295
Principal investigator 1 ABBVIE INC. $213.60 07/10/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202497854
Principal investigator 1 ABBVIE INC. $20,118.80 07/02/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494629
Principal investigator 1 ABBVIE INC. $683.40 06/26/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202493213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $265.00 06/19/2025 Non-covered Recipient Entity
DIABETES & THYROID CENTER OF FORT WORTH PLLC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223281628
Principal investigator 1 ABBVIE INC. $44,370.30 06/03/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488219
Principal investigator 1 ABBVIE INC. $630.11 05/13/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484679
Principal investigator 1 ABBVIE INC. $2,466.06 05/13/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484687
Principal investigator 1 ABBVIE INC. $648.08 05/12/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484627
Principal investigator 1 ABBVIE INC. $984.10 05/07/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482383
Principal investigator 1 ABBVIE INC. $845.26 05/07/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482385
Principal investigator 1 ABBVIE INC. $815.00 05/07/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482387
Principal investigator 1 ABBVIE INC. $18,648.50 05/07/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482429
Principal investigator 1 ABBVIE INC. $618.72 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480689
Principal investigator 1 ABBVIE INC. $210.30 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480691
Principal investigator 1 ABBVIE INC. $221.28 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480693
Principal investigator 1 ABBVIE INC. $487.68 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480703
Principal investigator 1 ABBVIE INC. $195.00 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480705
Principal investigator 1 ABBVIE INC. $195.00 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480707
Principal investigator 1 ABBVIE INC. $213.29 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480709
Principal investigator 1 ABBVIE INC. $195.00 05/01/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480711
Principal investigator 1 ABBVIE INC. $454.62 04/30/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480521
Principal investigator 1 ABBVIE INC. $223.81 04/30/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480537
Principal investigator 1 ABBVIE INC. $17,196.40 04/03/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202470227
Principal investigator 1 ABBVIE INC. $19,438.90 03/07/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459106
Principal investigator 1 Eli Lilly and Company $375.50 02/25/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187879857
Principal investigator 1 ABBVIE INC. $16,940.30 02/06/2025 Non-covered Recipient Entity
DIABETES & THYROID CTR OF FT WORTH
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447910
Principal investigator 1 Eli Lilly and Company $312.55 01/31/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187881356
Principal investigator 1 Eli Lilly and Company $844.93 01/27/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187878851
Principal investigator 1 Eli Lilly and Company $53,818.00 01/21/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187879853
Principal investigator 1 Eli Lilly and Company $43,028.00 01/21/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187882358
Principal investigator 1 Eli Lilly and Company $74,802.00 01/07/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187879855
Principal investigator 1 Eli Lilly and Company $1,467.88 01/07/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187881350
Principal investigator 1 Eli Lilly and Company $10,911.00 01/07/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187881352
Principal investigator 1 Eli Lilly and Company $48,625.00 01/07/2025 Non-covered Recipient Entity
DIABETES AND THYROID CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187881354